TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15742419

Group type: EXPERIMENTAL
Intervention: Somatostatin group (250 microg/h for 72 h)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Somatostatin group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Basic treatment group
Number of subjects: 60
Study: 12057725

Group type: EXPERIMENTAL
Intervention: Ovarian stimulation with FSH under pituitary suppression
Number of subjects: 88
Study: 9854759

Group type: EXPERIMENTAL
Intervention: Control of early morning lumbar flexion
Number of subjects: 85

Group type: COMPARATOR
Intervention: Sham treatment of six ineffective exercises
Number of subjects: 85
Study: 7833257

Group type: EXPERIMENTAL
Intervention: anti-D (20 micrograms/kg)
Number of subjects: 43

Group type: COMPARATOR
Intervention: saline placebo
Number of subjects: 43
Study: 2142237

Group type: EXPERIMENTAL
Intervention: 20 mg toremifene daily for 7 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 68 mg toremifene for 5 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 60 mg tamoxifen for 5 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Estrogen only (control group)
Number of subjects: 0
Study: 426267

Group type: EXPERIMENTAL
Intervention: Low-dose heparin
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (19 patients)
Number of subjects: 22
Study: 31999175

Group type: EXPERIMENTAL
Intervention: Telephone-based intervention (4 weekly calls + 5 biweekly calls)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Telephone-based intervention
Number of subjects: 33
Study: 31274183

Group type: EXPERIMENTAL
Intervention: High-dose Sandostatin LAR monotherapy (40 mg)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: High-dose Sandostatin LAR plus pegvisomant
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: High-dose Sandostatin LAR plus cabergoline
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: High-dose Sandostatin LAR monotherapy
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: High-dose Sandostatin LAR (all groups)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: All treatments (including combinations)
Number of subjects: 68
Study: 26975313

Group type: EXPERIMENTAL
Intervention: Nintendo Wii Sports™ (WiiTM)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Arm exercises at home
Number of subjects: 240
Study: 27067612

Group type: EXPERIMENTAL
Intervention: Myofascial therapy protocol (21 minutes)
Number of subjects: 30
Study: 24338522

Group type: EXPERIMENTAL
Intervention: Generic medication switches
Number of subjects: 28

Group type: COMPARATOR
Intervention: Confusion due to medication changes
Number of subjects: 28

Group type: COMPARATOR
Intervention: No problems with medication changes
Number of subjects: 28
Study: 23166441

Group type: EXPERIMENTAL
Intervention: Exenatide once weekly
Number of subjects: 211

Group type: COMPARATOR
Intervention: Exenatide once weekly and twice daily
Number of subjects: 211
Study: 19220959

Group type: EXPERIMENTAL
Intervention: Reduced Glutathione (GSH) for 7‐14 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Energy mixture (Control)
Number of subjects: 40
Study: 17553207

Group type: EXPERIMENTAL
Intervention: Zoledronic acid 4 mg intravenously every 3 months
Number of subjects: 215

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215
Study: 15541406

Group type: EXPERIMENTAL
Intervention: 200 mg vitamin E daily
Number of subjects: 486

Group type: EXPERIMENTAL
Intervention: 80 mg aspirin daily
Number of subjects: 486

Group type: EXPERIMENTAL
Intervention: Combination of vitamin E and low-dose aspirin
Number of subjects: 486

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 486
Study: 11558863

Group type: EXPERIMENTAL
Intervention: Olopatadine hydrochloride 0.1% ophthalmic solution
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Azelastine hydrochloride 0.05% ophthalmic solution
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo (artificial tears)
Number of subjects: 111
Study: 9156269

Group type: EXPERIMENTAL
Intervention: Tetanus toxoid (TT) vaccine at 6, 8 and 14 months after BMT (early group, n = 23)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Tetanus toxoid (TT) vaccine at 18, 20 and 26 months after BMT (late group, n = 22)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Tetanus toxoid (TT) vaccine (both groups)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Tetanus toxoid (TT) vaccine (late group)
Number of subjects: 45
Study: 8438741

Group type: EXPERIMENTAL
Intervention: Propafenone
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sotalol
Number of subjects: 100
Study: 3028699

Group type: EXPERIMENTAL
Intervention: High fibre diet for 6 weeks
Number of subjects: 88

Group type: COMPARATOR
Intervention: Low fibre diet throughout
Number of subjects: 88
Study: 29024120

Group type: EXPERIMENTAL
Intervention: Teriparatide (20 μg/d)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Denosumab (60 mg once/6 months)
Number of subjects: 69
Study: 27146000

Group type: EXPERIMENTAL
Intervention: Single oral dose of 1.6104 CFU of WRSS1 vaccine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 20
Study: 25608849

Group type: EXPERIMENTAL
Intervention: AG‐dieckol (1500 mg per day)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 23264069

Group type: EXPERIMENTAL
Intervention: 25% lingual dextrose
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 0
Study: 21040534

Group type: EXPERIMENTAL
Intervention: Screening program for Q fever with immediate analysis of blood samples for IgG and IgM antibodies using a cut-off level of 1:32.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group with serum frozen for analysis after delivery.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis comparing direct and indirect costs between intervention and control groups.
Number of subjects: 0
Study: 18237574

Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich diet (58% carbohydrate, 15% protein, 27% fat)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Higher protein diet (48% carbohydrate, 25% protein, 27% fat)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Higher unsaturated fat diet (48% carbohydrate, 15% protein, 37% fat)
Number of subjects: 164
Study: 12803267

Group type: EXPERIMENTAL
Intervention: Combined peri- and retrobulbar block
Number of subjects: 20

Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 20
Study: 9583341

Group type: EXPERIMENTAL
Intervention: Complete cognitive-behavioral therapy (CT)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Behavioral activation
Number of subjects: 137

Group type: COMPARATOR
Intervention: Behavioral activation with automatic thought modification
Number of subjects: 137
Study: 7624197

Group type: EXPERIMENTAL
Intervention: Colored environment 1
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Colored environment 2
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Colored environment 3
Number of subjects: 15
Study: 2539762

Group type: COMPARATOR
Intervention: Quinapril 10 mg once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Quinapril 20 mg once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Quinapril 5 mg once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Quinapril administered once or twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Quinapril in patients with refractory congestive heart failure
Number of subjects: 0
Study: 335790

Group type: EXPERIMENTAL
Intervention: L-tryptophan (6 g daily) with unilateral ECT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo with unilateral ECT
Number of subjects: 0
Study: 31044267

Group type: EXPERIMENTAL
Intervention: Bendamustine/Rituximab plus Ibrutinib (BR-I)
Number of subjects: 578

Group type: COMPARATOR
Intervention: Bendamustine/Rituximab plus Placebo (BR)
Number of subjects: 578
Study: 26703983

Group type: EXPERIMENTAL
Intervention: Disease-specific nutritional formula enriched with arginine, zinc, and antioxidants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Isocaloric-isonitrogenous support
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Disease-specific nutritional formula
Number of subjects: 0
Study: 25925670

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture at Neiguan (PC6)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture at a non-acupoint
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no acupuncture)
Number of subjects: 60
Study: 24068631

Group type: EXPERIMENTAL
Intervention: Fenofibrate (160 mg/day for 6 weeks)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: ER-niacin (0.5 g/day for 3 weeks, then 1 g/day for 6 weeks)
Number of subjects: 66
Study: 21378388

Group type: EXPERIMENTAL
Intervention: Troponin I (TnI) assessment at 24 hours (> 6.6 μg/l)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Creatine kinase-MB isoform (CK-MB) assessment
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Area under the curve for TnI
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Area under the curve for CK-MB
Number of subjects: 40
Study: 19151379

Group type: EXPERIMENTAL
Intervention: LASIK
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: PRK
Number of subjects: 46
Study: 17947376

Group type: EXPERIMENTAL
Intervention: PCOS group
Number of subjects: 40
Study: 15472216

Group type: EXPERIMENTAL
Intervention: rhGH treatment (6 mg/d) for 3 months
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 11721171

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (anthracycline-based) for TCRBCL patients
Number of subjects: 10

Group type: COMPARATOR
Intervention: Combination chemotherapy (anthracycline-based) for DLBCL patients
Number of subjects: 10
Study: 9720463

Group type: EXPERIMENTAL
Intervention: Improved satisfaction with the physical workstation
Number of subjects: 577

Group type: EXPERIMENTAL
Intervention: Improved chair comfort
Number of subjects: 577

Group type: EXPERIMENTAL
Intervention: Fewer housekeeping responsibilities
Number of subjects: 577

Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 577

Group type: EXPERIMENTAL
Intervention: Low pay range
Number of subjects: 577
Study: 8172273

Group type: EXPERIMENTAL
Intervention: Pranoprofen 0.1%
Number of subjects: 151

Group type: COMPARATOR
Intervention: Fluorometholone 0.1%
Number of subjects: 151
Study: 3145746

Group type: EXPERIMENTAL
Intervention: Pravastatin 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31375440

Group type: EXPERIMENTAL
Intervention: 7.5mcg or 15mcg of hemagglutinin (HA)/dose for children 6-35 months; 15mcg HA/dose for children 3-17 years, administered via intramuscular injection, two doses 21 days apart.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: H3N2v vaccine
Number of subjects: 0
Study: 28124817

Group type: EXPERIMENTAL
Intervention: Once-weekly titration of IDegLira (based on mean of 2 pre-breakfast PG readings)
Number of subjects: 420

Group type: COMPARATOR
Intervention: Twice-weekly titration of IDegLira (based on mean of 3 pre-breakfast PG readings)
Number of subjects: 420
Study: 26106626

Group type: EXPERIMENTAL
Intervention: 40 μg/d vitamin D3
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: 80 μg/d vitamin D3
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 23499427

Group type: EXPERIMENTAL
Intervention: Detection of depression and/or anxiety
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Complaints suggestive of underlying depressive and/or anxiety disorders
Number of subjects: 200
Study: 21471758

Group type: EXPERIMENTAL
Intervention: Methylnaltrexone 12 mg
Number of subjects: 1048

Group type: EXPERIMENTAL
Intervention: Methylnaltrexone 24 mg
Number of subjects: 1048

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1048
Study: 19964412

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation of the subthalamic nucleus (STN DBS) alone
Number of subjects: 45

Group type: COMPARATOR
Intervention: Medication
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Combined treatments (STN DBS + medication)
Number of subjects: 45

Group type: COMPARATOR
Intervention: No treatment (mof-sof)
Number of subjects: 45
Study: 17242254

Group type: EXPERIMENTAL
Intervention: Chemoradiation therapy (standardized 5-week course)
Number of subjects: 30
Study: 15494583

Group type: EXPERIMENTAL
Intervention: Bilateral arm training with rhythmic auditory cueing (BATRAC)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Standardized dose‐matched therapeutic exercises (DMTE)
Number of subjects: 21
Study: 11448094

Group type: EXPERIMENTAL
Intervention: Haloperidol (1 mg i.v.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chlorpromazine (100 mg p.o.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg p.o.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lorazepam (2 mg p.o.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9506206

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (Gamimune N)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 62
Study: 7871106

Group type: EXPERIMENTAL
Intervention: Fatigue‐non‐CFS group
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Patients with CFS
Number of subjects: 55

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 55
Study: 2463035

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) (Fragmin) 2500 anti-factor Xa units twice daily for 7 days
Number of subjects: 98

Group type: COMPARATOR
Intervention: Dextran 70 (Macrodex) 500 ml twice during the day of operation, followed by a single infusion of 500 ml on the first and again on the third postoperative day
Number of subjects: 98
Study: 29032903

Group type: EXPERIMENTAL
Intervention: Single-shot femoral nerve block
Number of subjects: 43

Group type: COMPARATOR
Intervention: Local infiltration anesthesia (Control)
Number of subjects: 43
Study: 27285306

Group type: EXPERIMENTAL
Intervention: Combined hormonal vaginal ring (CVR)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Combined hormonal pills (CHP)
Number of subjects: 50
Study: 25473945

Group type: EXPERIMENTAL
Intervention: Teleophthalmologic group
Number of subjects: 169

Group type: COMPARATOR
Intervention: Routine group
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 169
Study: 23024246

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 139

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study: 19861236

Group type: EXPERIMENTAL
Intervention: Middle third patellar tendon graft (PT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Leeds-Keio synthetic graft (LK)
Number of subjects: 50
Study: 18420320

Group type: EXPERIMENTAL
Intervention: Dermis-fat graft interposition after arthroplasty
Number of subjects: 17

Group type: COMPARATOR
Intervention: Temporalis fascia interposition
Number of subjects: 17
Study: 16838876

Group type: EXPERIMENTAL
Intervention: Chewing gum with sodium hexametaphosphate (4%)
Number of subjects: 54

Group type: COMPARATOR
Intervention: No-gum group
Number of subjects: 54
Study: 12619672

Group type: EXPERIMENTAL
Intervention: Medium-chain triglycerides (MCT)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Long-chain triglycerides (LCT)
Number of subjects: 25
Study: 11050588

Group type: EXPERIMENTAL
Intervention: 0.6% ajoene
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 1% ajoene
Number of subjects: 70

Group type: COMPARATOR
Intervention: 1% terbinafine
Number of subjects: 70
Study: 9255326

Group type: EXPERIMENTAL
Intervention: Plasma exchanges (PE)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (CS without PE)
Number of subjects: 32
Study: 1345694

Group type: EXPERIMENTAL
Intervention: Dobutamine infusion (10 mcg/kg.min for 1 hour)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Conventional therapy plus dobutamine (D+) for 9 consecutive days
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional therapy only (D-)
Number of subjects: 50
Study: 3877290

Group type: EXPERIMENTAL
Intervention: Propofol ('Diprivan') 1.5 mg/kg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Thiopentone 2 mg/kg
Number of subjects: 20
Study: 31860972

Group type: EXPERIMENTAL
Intervention: Epi-off accelerated corneal collagen crosslinking (CXL) with epithelial abrasion and 18 mW/cm ultraviolet A irradiation for 5 minutes
Number of subjects: 23

Group type: COMPARATOR
Intervention: 5% NaCl hypertonic saline (HS) instillation
Number of subjects: 23
Study: 27417000

Group type: EXPERIMENTAL
Intervention: Sacubitril/Valsartan (LCZ696)
Number of subjects: 8399

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 8399
Study: 23582501

Group type: EXPERIMENTAL
Intervention: Chloral hydrate (CH) 38±14.73mg/kg
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Hydroxyzine 1.43±0.74mg/kg
Number of subjects: 341

Group type: COMPARATOR
Intervention: Control group (no medication)
Number of subjects: 341
Study: 21736700

Group type: EXPERIMENTAL
Intervention: Peer counselling promoting exclusive breast or formula feeding
Number of subjects: 17
Study: 20687982

Group type: EXPERIMENTAL
Intervention: Mometasone furoate/formoterol 400/10 microg
Number of subjects: 728

Group type: EXPERIMENTAL
Intervention: Mometasone furoate/formoterol 200/10 microg
Number of subjects: 728
Study: 18588696

Group type: EXPERIMENTAL
Intervention: Intervention group (exposed to biasing prompts)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Control group (not exposed to biasing prompts)
Number of subjects: 163
Study: 16093575

Group type: EXPERIMENTAL
Intervention: Troglitazone (400 mg daily for eight weeks)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Troglitazone
Number of subjects: 15
Study: 12814141

Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol (up to 3100 microg)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Not applicable (control group)
Number of subjects: 38
Study: 11043615

Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study: 8785636

Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Bone Scintigraphy (BS)
Number of subjects: 59
Study: 1338388

Group type: EXPERIMENTAL
Intervention: Fluoxetine 60 mg daily
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study: 4053114

Group type: EXPERIMENTAL
Intervention: Clinical history and simple bedside evaluation
Number of subjects: 698

Group type: EXPERIMENTAL
Intervention: Serum enzyme activity
Number of subjects: 698

Group type: EXPERIMENTAL
Intervention: 2‐year survival
Number of subjects: 698

Group type: EXPERIMENTAL
Intervention: Incidence and severity of congestive heart failure
Number of subjects: 698

Group type: EXPERIMENTAL
Intervention: Incidence of severe ventricular arrhythmias during initial hospitalization
Number of subjects: 698
Study: 31437476

Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (MBI) for 8 weeks
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (MBI)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 26
Study: 29068818

Group type: EXPERIMENTAL
Intervention: Simulation-based mastery learning (SBML)
Number of subjects: 709

Group type: COMPARATOR
Intervention: Control group (traditionally trained residents)
Number of subjects: 709

Group type: COMPARATOR
Intervention: Control group (pulmonary and IR referrals)
Number of subjects: 709
Study: 26661717

Group type: EXPERIMENTAL
Intervention: MyMediHealth (MMH) - SMS reminders for 3 weeks
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control - action lists as part of usual care
Number of subjects: 98
Study: 23850157

Group type: EXPERIMENTAL
Intervention: Micro-structured calcium phosphate ceramic
Number of subjects: 20
Study: 22751087

Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 23
Study: 19856249

Group type: EXPERIMENTAL
Intervention: 4-h single serum method using dual stable isotopes
Number of subjects: 19

Group type: COMPARATOR
Intervention: 24-h urine method
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Comparison of both methods
Number of subjects: 19
Study: 18090695

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 31

Group type: COMPARATOR
Intervention: Thiopental
Number of subjects: 31
Study: 15671606

Group type: EXPERIMENTAL
Intervention: Tirofiban + Heparin (Group III)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Tirofiban + Dalteparin (Group IV)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Heparin alone (Group I)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Dalteparin alone (Group II)
Number of subjects: 160
Study: 11547294

Group type: EXPERIMENTAL
Intervention: Aprotinin (2 x 10(6) kallikrein inhibiting units)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 9595364

Group type: EXPERIMENTAL
Intervention: 1 abnormal OGTT value
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: GDM
Number of subjects: 325

Group type: COMPARATOR
Intervention: Control (normal OGTT)
Number of subjects: 325
Study: 7996404

Group type: EXPERIMENTAL
Intervention: Can-opener capsulotomy
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Retained anterior capsule flap
Number of subjects: 57

Group type: COMPARATOR
Intervention: Comparison of both techniques
Number of subjects: 57
Study: 2887623

Group type: EXPERIMENTAL
Intervention: 2% sodium cromoglycate plus 0.025% xylometazoline
Number of subjects: 40

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 40
Study: 29914463

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) intervention consisting of two MI sessions offered by caseworkers at the Norwegian Labor and Welfare Service (NAV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Group that receives two extra sessions without MI content (to control for attentional bias)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) intervention
Number of subjects: 0
Study: 26733274

Group type: EXPERIMENTAL
Intervention: IV PCA + SSNB + ANB
Number of subjects: 114

Group type: COMPARATOR
Intervention: IV PCA + SSNB
Number of subjects: 114

Group type: COMPARATOR
Intervention: IV PCA (only PCA)
Number of subjects: 114
Study: 23563646

Group type: EXPERIMENTAL
Intervention: Moderate pressure MCSs (23-32 mmHg, group B)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Low pressure MCSs (18-21 mmHg, group A)
Number of subjects: 88